Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

cevostamab

A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FCRH5; CD307; FCRL5; IRTA2; BXMAS1) and one that is directed against the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of cevostamab, the bispecific antibody binds to both the CD3 antigen on cytotoxic T lymphocytes (CTLs) and FCRH5 found on FCRH5-expressing tumor cells. This activates and crosslinks CTLs with FCRH5-expressing tumor cells, which results in the CTL-mediated cell death of FCRH5-expressing tumor cells. FCRH5, an immune receptor translocation-associated protein/Fc receptor homolog (IRTA/FCRH) family member and a B-cell lineage marker, is overexpressed on myeloma cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-FCRH5 x anti-CD3 bi-specific T-cell engager BFCR4350A
anti-FCRH5/CD3 BiTE antibody BFCR4350A
anti-FCRH5/CD3 TDB BFCR4350A
FCRH5/CD3 T Cell dependent bispecific antibody BFCR4350A
FCRH5/CD3 T-cell-dependent bispecific antibody BFCR4350A
FCRH5/CD3 TDB antibody BFCR4350A
recombinant anti-FCRH5 x anti-CD3 bi-specific T-cell engager BFCR4350A
Code name:BFCR4350A
RO7187797
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search